National Medicare Coverage Policies For Genetic Tests Suggested By Insurers
This article was originally published in The Pink Sheet Daily
Executive Summary
In response to a CMS call for input on revising its list of potential candidates for national coverage determinations in Medicare, AHIP suggests the agency stop relying on local carriers to determine payment for genetic tests. Biopharmaceutical groups raise concerns that CMS may be signaling a move toward a new standard for Medicare coverage.
You may also be interested in...
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.